Last reviewed · How we verify
Yong Seog Oh — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Continuous heparin infusion | Continuous heparin infusion | phase 3 | Anticoagulant | Thrombin (Factor IIa), Factor Xa, Antithrombin III | Cardiovascular | |
| Adenosine arm | Adenosine arm | phase 3 | Adenosine receptors (A1, A2A, A2B, A3) | |||
| Intermittent heparin infusion | Intermittent heparin infusion | phase 3 | Anticoagulant | Thrombin (Factor IIa), Factor Xa, Antithrombin III | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 2
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Beijing Anzhen Hospital · 1 shared drug class
- Beijing Chao Yang Hospital · 1 shared drug class
- Beijing Suncadia Pharmaceuticals Co., Ltd · 1 shared drug class
- Boston Scientific Corporation · 1 shared drug class
- CCRF Consulting Co., Ltd. · 1 shared drug class
- Deutsches Herzzentrum Muenchen · 1 shared drug class
- Anemia Working Group Romania · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Yong Seog Oh:
- Yong Seog Oh pipeline updates — RSS
- Yong Seog Oh pipeline updates — Atom
- Yong Seog Oh pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Yong Seog Oh — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yong-seog-oh. Accessed 2026-05-16.